TY - JOUR
T1 - Recent Insights into the Protective Mechanisms of Paeoniflorin in Neurological, Cardiovascular, and Renal Diseases
AU - Jiao, Feng
AU - Varghese, Kevin
AU - Wang, Shaoxun
AU - Liu, Yedan
AU - Yu, Hongwei
AU - Booz, George W.
AU - Roman, Richard J.
AU - Liu, Ruen
AU - Fan, Fan
N1 - Funding Information:
Supported by the National Institutes of Health (AG050049, AG057842, P20GM104357, DK104184, and HL138685); the American Heart Association (16GRNT31200036 and 20PRE35210043); and the Ministry of Science and Technology of the People's Republic of China (2019YEF0117100).
Publisher Copyright:
© 2021 Lippincott Williams and Wilkins. All rights reserved.
PY - 2021/6/19
Y1 - 2021/6/19
N2 - The monoterpene glycoside paeoniflorin (PF) is the principal active constituent of the traditional Chinese herbal medicines, Radix Paeoniae Alba and Radix Paeoniae Rubra, which have been used for millennia to treat cardiovascular diseases (eg, hypertension, bleeding, and atherosclerosis) and neurological ailments (eg, headaches, vertigo, dementia, and pain). Recent evidence has revealed that PF exerts inhibitory effects on inflammation, fibrosis, and apoptosis by targeting several intracellular signaling cascades. In this review, we address the current knowledge about the pharmacokinetic properties of PF and its molecular mechanisms of action. We also present results from recent preclinical studies supporting the utility of PF for the treatment of pain, cerebral ischemic injury, and neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Moreover, new evidence suggests a general protective role of PF in heart attack, diabetic kidney, and atherosclerosis. Mechanistically, PF exerts multiple anti-inflammatory actions by targeting toll-like receptor-mediated signaling in both parenchymal and immune cells (in particular, macrophages and dendritic cells). A better understanding of the molecular actions of PF may lead to the expansion of its therapeutic uses.
AB - The monoterpene glycoside paeoniflorin (PF) is the principal active constituent of the traditional Chinese herbal medicines, Radix Paeoniae Alba and Radix Paeoniae Rubra, which have been used for millennia to treat cardiovascular diseases (eg, hypertension, bleeding, and atherosclerosis) and neurological ailments (eg, headaches, vertigo, dementia, and pain). Recent evidence has revealed that PF exerts inhibitory effects on inflammation, fibrosis, and apoptosis by targeting several intracellular signaling cascades. In this review, we address the current knowledge about the pharmacokinetic properties of PF and its molecular mechanisms of action. We also present results from recent preclinical studies supporting the utility of PF for the treatment of pain, cerebral ischemic injury, and neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Moreover, new evidence suggests a general protective role of PF in heart attack, diabetic kidney, and atherosclerosis. Mechanistically, PF exerts multiple anti-inflammatory actions by targeting toll-like receptor-mediated signaling in both parenchymal and immune cells (in particular, macrophages and dendritic cells). A better understanding of the molecular actions of PF may lead to the expansion of its therapeutic uses.
KW - cardiac remodeling
KW - cardiovascular disease
KW - diabetic nephropathy
KW - inflammation
KW - traditional Chinese medicines
UR - http://www.scopus.com/inward/record.url?scp=85107318930&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107318930&partnerID=8YFLogxK
U2 - 10.1097/FJC.0000000000001021
DO - 10.1097/FJC.0000000000001021
M3 - Review article
C2 - 34001724
AN - SCOPUS:85107318930
SN - 0160-2446
VL - 77
SP - 728
EP - 734
JO - Journal of Cardiovascular Pharmacology
JF - Journal of Cardiovascular Pharmacology
IS - 6
ER -